SciTech Development Attending 38th Annual J.P. Morgan Healthcare Conference

 
GROSSE POINTE, Mich. - Nov. 22, 2019 - PRLog -- SciTech Development is pleased to announce that it will be attending the J.P. Morgan Healthcare Conference January 12–16 in San Francisco, CA. SciTech will be participating in the BIO One-on-One Partnering™ @ JPM.

For one-on-one meetings @ JPM contact Earle Holsapple (+1-313-938-5517) or Don Zinn (+1-269-569-2794) to discuss ST-001 nanoFenretinide investment and partnering opportunities. SciTech Development's proprietary nanoparticle drug delivery system (SciTech Drug Delivery Vehicle - SDV) enables intravenous (IV) delivery of water-insoluble (or hydrophobic) drugs. Fenretinide, SciTech's lead API (active pharmaceutical ingredient), has been shown in numerous clinical trials to be a safe and effective anticancer therapy with targeted cancer destroying activity; however, its poor bioavailability has impeded its development as a drug. The patented combination of SciTech's new SDV and the fenretinide API has led to the company's lead drug candidate ST-001 nanoFenretinide with enhanced bioavailability (water solubilized) for the treatment of non-Hodgkin's T-cell lymphoma. SciTech is actively seeking funding and strategic partnerships to conduct a Phase 1A & 1B clinical trial to reconfirm the safety and efficacy of fenretinide in its new nanoFenretinide formulation while also confirming a newly identified immune MOA (mechanism of action) as a further goal of the protocol. For more info, visit https://www.scitechdevelopment.com/.

About SciTech Development
SciTech Development, LLC is a clinical stage drug development company bringing to market a proven cancer drug for diseases with limited therapeutic options. SciTech Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland.

Forward-Looking InformationThis press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC ("the Company"), future expectations, plans and prospects. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.

Contact
Louis M. Scarmoutzos, Ph.D.
***@scitechdevelopment.com
End
Source: » Follow
Email:***@scitechdevelopment.com Email Verified
Tags:nanoFenretinide
Industry:Biotech
Location:Grosse Pointe - Michigan - United States
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SciTech Development LLC News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share